vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Gitlab Inc. (GTLB). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $244.4M, roughly 2.0× Gitlab Inc.). Gitlab Inc. runs the higher net margin — -3.4% vs -10.1%, a 6.7% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 24.6%). Gitlab Inc. produced more free cash flow last quarter ($28.4M vs $-69.0M). Over the past eight quarters, Gitlab Inc.'s revenue compounded faster (22.1% CAGR vs 18.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

GitLab Inc. is an American company that operates and develops GitLab, an open-core DevOps software package that can develop, secure, and operate software. GitLab includes a distributed version control system based on Git, including features such as access control, bug tracking, software feature requests, task management, and wikis for every project, as well as snippets.

CLOV vs GTLB — Head-to-Head

Bigger by revenue
CLOV
CLOV
2.0× larger
CLOV
$487.7M
$244.4M
GTLB
Growing faster (revenue YoY)
CLOV
CLOV
+20.1% gap
CLOV
44.7%
24.6%
GTLB
Higher net margin
GTLB
GTLB
6.7% more per $
GTLB
-3.4%
-10.1%
CLOV
More free cash flow
GTLB
GTLB
$97.4M more FCF
GTLB
$28.4M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
GTLB
GTLB
Annualised
GTLB
22.1%
18.6%
CLOV

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
CLOV
CLOV
GTLB
GTLB
Revenue
$487.7M
$244.4M
Net Profit
$-49.3M
$-8.3M
Gross Margin
86.8%
Operating Margin
-10.1%
-5.1%
Net Margin
-10.1%
-3.4%
Revenue YoY
44.7%
24.6%
Net Profit YoY
-123.2%
-128.0%
EPS (diluted)
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
GTLB
GTLB
Q4 25
$487.7M
$244.4M
Q3 25
$496.6M
$236.0M
Q2 25
$477.6M
$214.5M
Q1 25
$462.3M
$211.4M
Q4 24
$337.0M
$196.0M
Q3 24
$331.0M
$182.6M
Q2 24
$356.3M
$169.2M
Q1 24
$346.9M
$163.8M
Net Profit
CLOV
CLOV
GTLB
GTLB
Q4 25
$-49.3M
$-8.3M
Q3 25
$-24.4M
$-9.2M
Q2 25
$-10.6M
$-35.9M
Q1 25
$-1.3M
$5.8M
Q4 24
$-22.1M
$29.6M
Q3 24
$-9.2M
$12.9M
Q2 24
$7.4M
$-54.6M
Q1 24
$-19.2M
$-36.5M
Gross Margin
CLOV
CLOV
GTLB
GTLB
Q4 25
86.8%
Q3 25
87.9%
Q2 25
88.3%
Q1 25
89.2%
Q4 24
88.7%
Q3 24
24.5%
88.3%
Q2 24
30.3%
88.9%
Q1 24
23.6%
90.2%
Operating Margin
CLOV
CLOV
GTLB
GTLB
Q4 25
-10.1%
-5.1%
Q3 25
-4.9%
-7.8%
Q2 25
-2.2%
-16.1%
Q1 25
-0.3%
-9.1%
Q4 24
-6.4%
-14.7%
Q3 24
-2.7%
-22.5%
Q2 24
2.0%
-31.7%
Q1 24
-6.5%
-21.3%
Net Margin
CLOV
CLOV
GTLB
GTLB
Q4 25
-10.1%
-3.4%
Q3 25
-4.9%
-3.9%
Q2 25
-2.2%
-16.7%
Q1 25
-0.3%
2.7%
Q4 24
-6.6%
15.1%
Q3 24
-2.8%
7.1%
Q2 24
2.1%
-32.3%
Q1 24
-5.5%
-22.3%
EPS (diluted)
CLOV
CLOV
GTLB
GTLB
Q4 25
$-0.05
Q3 25
$-0.06
Q2 25
$-0.22
Q1 25
$0.05
Q4 24
$0.18
Q3 24
$0.08
Q2 24
$-0.35
Q1 24
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
GTLB
GTLB
Cash + ST InvestmentsLiquidity on hand
$78.3M
$224.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$922.7M
Total Assets
$541.0M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
GTLB
GTLB
Q4 25
$78.3M
$224.2M
Q3 25
$261.4M
Q2 25
$255.7M
Q1 25
$227.6M
Q4 24
$194.5M
$176.6M
Q3 24
$288.0M
$438.6M
Q2 24
$254.8M
$420.3M
Q1 24
$208.3M
$288.0M
Stockholders' Equity
CLOV
CLOV
GTLB
GTLB
Q4 25
$308.7M
$922.7M
Q3 25
$340.9M
$866.6M
Q2 25
$344.2M
$808.3M
Q1 25
$336.1M
$775.9M
Q4 24
$341.1M
$724.7M
Q3 24
$342.2M
$642.8M
Q2 24
$324.9M
$567.8M
Q1 24
$292.5M
$571.2M
Total Assets
CLOV
CLOV
GTLB
GTLB
Q4 25
$541.0M
$1.6B
Q3 25
$559.7M
$1.5B
Q2 25
$575.0M
$1.4B
Q1 25
$583.7M
$1.4B
Q4 24
$580.7M
$1.3B
Q3 24
$653.0M
$1.4B
Q2 24
$674.2M
$1.3B
Q1 24
$671.8M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
GTLB
GTLB
Operating Cash FlowLast quarter
$-66.9M
$31.4M
Free Cash FlowOCF − Capex
$-69.0M
$28.4M
FCF MarginFCF / Revenue
-14.1%
11.6%
Capex IntensityCapex / Revenue
0.4%
1.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$242.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
GTLB
GTLB
Q4 25
$-66.9M
$31.4M
Q3 25
$12.1M
$49.4M
Q2 25
$5.4M
$106.3M
Q1 25
$-16.3M
$63.2M
Q4 24
$34.8M
$-177.0M
Q3 24
$50.0M
$11.7M
Q2 24
$44.8M
$38.1M
Q1 24
$25.9M
$24.9M
Free Cash Flow
CLOV
CLOV
GTLB
GTLB
Q4 25
$-69.0M
$28.4M
Q3 25
$11.4M
$46.5M
Q2 25
$4.8M
$105.4M
Q1 25
$-16.5M
$62.1M
Q4 24
$33.3M
$-178.1M
Q3 24
$49.6M
$10.8M
Q2 24
$44.4M
$37.4M
Q1 24
$25.5M
$24.5M
FCF Margin
CLOV
CLOV
GTLB
GTLB
Q4 25
-14.1%
11.6%
Q3 25
2.3%
19.7%
Q2 25
1.0%
49.1%
Q1 25
-3.6%
29.4%
Q4 24
9.9%
-90.8%
Q3 24
15.0%
5.9%
Q2 24
12.5%
22.1%
Q1 24
7.3%
15.0%
Capex Intensity
CLOV
CLOV
GTLB
GTLB
Q4 25
0.4%
1.2%
Q3 25
0.1%
1.2%
Q2 25
0.1%
0.4%
Q1 25
0.0%
0.5%
Q4 24
0.5%
0.5%
Q3 24
0.1%
0.5%
Q2 24
0.1%
0.4%
Q1 24
0.1%
0.2%
Cash Conversion
CLOV
CLOV
GTLB
GTLB
Q4 25
Q3 25
Q2 25
Q1 25
10.89×
Q4 24
-5.99×
Q3 24
0.90×
Q2 24
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

GTLB
GTLB

Subscription And Circulation$146.4M60%
Subscription Software As A Service$76.9M31%
License$15.5M6%
Professional Services And Other$5.6M2%

Related Comparisons